succimer (Rx)

Brand and Other Names:Chemet
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule

  • 100mg

Lead Poisoning (Off-label)

10 mg/kg PO q8hr for 5 days; follow by 10 mg/kg/dose q12hr for 14 days; not to exceed 500 mg/dose  

Chemical name: meso 2,3-dimercaptosuccinic acid (DMSA)

Arsenic Poisoning (Off-label)

300 mg PO q6hr for 3 days

End point: urinary arsenic <50 mcg/L

Cystine Kidney Stone (Orphan)

Prevention of cystine kidney stone formation in patients with homozygous cystinuria prone to stone development

Orphan indication sponsor

  • Sanofi Winthrop, Inc; 90 Park Ave; New York, NY 10016-1389

Mercury Intoxication (Orphan)

Treatment of mercury intoxication

Orphan indication sponsor

  • Sanofi Winthrop, Inc; 90 Park Ave; New York, NY 10016-1389

Other Information

Key point: Patient should maintain PO fluids

Forms water-soluble chelate with heavy metal (lead, also mercury and arsenic)

Recheck blood lead levels q14Days

Other Indications & Uses

Lead poisoning (child: >45-69 mcg/dL [2.17-3.33 micromoles/L])

Off-label: arsenic poisoning (in combination with BAL)

Dosage Forms & Strengths

capsule

  • 100mg

Lead Poisoning

<1 year: Safety and efficacy not established

1 year or older: Blood lead levels above 45 mcg/dL, 10 mg/kg or 350 mg/sq.meter q8hr for 5 days, then 10 mg/kg or 350 mg/sq.meter q12hr for 14 days  

Other Information

Key point: patient should maintain PO fluids

Recheck blood lead levels q14Days

Chemet: no data for combination with Na2CaEDTA

Lead Poisoning (Off-label)

10 mg/kg PO q8hr for 5 days; follow by 10 mg/kg/dose q12hr for 14 days; not to exceed 500 mg/dose  

Arsenic Poisoning (Off-label)

300 mg PO q6hr for 3 days

End point: urinary arsenic <50 mcg/L

Next:

Adverse Effects

Frequency Not Defined

Nausea/vomiting

Diarrhea

Abd gas/pain

Transient LFTs incr (AST, AP)

Rash

Pruritus

Sore throat

Rhinorrhea

Drowsiness

Paresthesia

Thrombocytosis

Eosinophilia

Possible decr renal function

Fever

Previous
Next:

Warnings

Contraindications

History of hypersensitivity to drug or excipients

Cautions

Clinical experience with product is limited; patients should be carefully observed during treatment

Keep out of reach of pediatric patients; product is not a substitute for effective abatement of lead exposure

Mild to moderate neutropenia reported; while causal relationship to drug not definitely established, neutropenia has been reported with other drugs in same chemical class; obtain complete blood count with white blood cell differential and direct platelet counts prior to and weekly during therapy; withhold therapy or discontinue if absolute neutrophil count (ANC) is below 1200/mcL and patient followed closely to document recovery of ANC to above 1500/mcL or to patient’s baseline neutrophil count; there is limited experience with reexposure in patients who have developed neutropenia; such patients should be rechallenged only if benefit of therapy clearly outweighs potential risk of another episode of neutropenia and then only with careful patient monitoring; patients treated with product should be instructed to promptly report any signs of infection; if infection suspected, the above laboratory tests should be conducted immediately

Elevated blood lead levels and associated symptoms may return rapidly after discontinuation of therapy because of redistribution of lead from bone stores to soft tissues and blood; after therapy, monitor patients for rebound of blood lead levels, by measuring blood lead levels at least once weekly until stable; however, severity of lead intoxication (as measured by initial blood lead level and rate and degree of rebound of blood lead) should be used as guide for more frequent blood lead monitoring

All patients undergoing treatment should be adequately hydrated; use caution in patients with compromised renal function; limited data suggests that product is dialyzable, but that the lead chelates are not

Transient mild elevations of serum transaminases observed in 6-10% of patients during course of therapy; monitor serum transaminases before start of therapy and at least weekly during therapy; monitor closely patients with a history of liver disease; no data are available regarding metabolism of drugs in patients with liver disease

Clinical experience with repeated courses limited; safety of uninterrupted dosing longer than three weeks not established and not recommended

Possibility of allergic or other mucocutaneous reactions to drug must be borne in mind on readministration (as well as during initial courses); patients requiring repeated courses of therapy should be monitored during each treatment course; one patient experienced recurrent mucocutaneous vesicular eruptions of increasing severity affecting the oral mucosa, external urethral meatus and perianal area on the third, fourth and fifth courses of therapy; the reaction resolved between courses and upon discontinuation of therapy

Previous
Next:

Pregnancy & Lactation

Pregnancy

Succimer has been shown to be teratogenic and fetotoxic in pregnant mice when given subcutaneously in a dose range of 410 to 1640 mg/kg/day during period of organogenesis; in a developmental study in rats, succimer produced maternal toxicity and deaths at the dose of 720 mg/kg/day or more during organogenesis

The dose of 510 mg/kg/day was the highest tolerable dose in pregnant rats; impaired development of reflexes was noted in pups of 720 mg/kg/day group dam; there are no adequate and well controlled studies in pregnant women; therapy should be administered during pregnancy only if potential benefit justifies potential risk to fetus

Lactation

Not known whether this drug is excreted in human milk; because many drugs and heavy metals are excreted in human milk, nursing mothers requiring therapy should be discouraged from nursing their infants

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

2 sulfhydryl groups capable of complexing to lead making it water soluble

Pharmacokinetics

Rapid but incomplete

Protein binding: Highly bound to albumin

Excretion: Feces (39%), urine (9%)

Time to peak: 1-2 hr (serum)

Half-life elimination: 2 days

Metabolism: Metabolized extensively to succimer cysteine sulfides

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.